Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $379.70M
Last updated: Nov 17, 2026 at 4:10 PM ET
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Statistics
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a market cap of $379.70M and an enterprise value of $304.50M. Its share count is up 36.54% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 19.80% below the market cap, as cash exceeds debt.
| Market Cap | $379.70M |
|---|---|
| Enterprise Value | $304.50M |
| Latest price (Nov 17, 2026) | $9.55 |
Key Dates
The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 10.41% over 52 weeks and trades 13.26% below its 50-day average.
| Beta (1Y) | 1.64 |
|---|---|
| 52-Week Change | -10.41% |
| 1-Month Change | +28.36% |
| 3-Month Change | -40.39% |
| 6-Month Change | -25.16% |
| Total Return (1Y) | -10.41% |
| Return vs SPY (1Y) | -28.59% |
| Max Drawdown (1Y) | -59.70% |
| Max Drawdown (3Y) | -84.37% |
| Sharpe Ratio (1Y) | -0.22 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $11.01 |
| 200-Day Average | $13.35 |
| 52-Week Range | $6.72 to $17.79 |
| RSI (14 Days) | 45.8 |
| Average Volume (20 Days) | 466.96K |
Financial Position
Current assets cover 31.11x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 31.11x |
|---|---|
| Quick Ratio | 31.11x |
| Debt / Equity | 0.00x |
| Interest Coverage | 90.25x |
Returns and Efficiency
Return on equity is -25.86% and return on assets is -24.69% over the last 12 months.
| Return on Equity (ROE) | -25.86% |
|---|---|
| Return on Assets (ROA) | -24.69% |
| ROA (5Y Average) | -22.63% |
Scores
CTNM has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$85.00K |
| Operating Income | -$72.41M |
| Pretax Income | -$63.46M |
| Net Income | -$63.46M |
| Reported EPS (TTM) | -$1.77 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 95.50% of the $256.99M in total assets.
| Cash and Equivalents | $75.20M |
|---|---|
| Total Debt | $0 |
| Net Cash | $75.20M |
| Net Cash Per Share | $1.96 |
| Working Capital | $241.72M |
| Shareholder Equity | $245.42M |
| Book Value Per Share | $6.39 |
| Total Assets | $256.99M |
| Total Liabilities | $11.57M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$51.87M |
|---|---|
| FCF Per Share | -$1.58 |
| Depreciation and Amortization | $2.40M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
CTNM does not pay a dividend.
| Buyback Yield | -30.74% |
|---|---|
| Shareholder Yield | -30.74% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CTNM
What is CTNM's market cap?
Contineum Therapeutics, Inc. Class A Common Stock has a market cap of $379.70M. Its enterprise value, which adds debt and subtracts cash, is $304.50M.
How many shares of CTNM are outstanding?
Contineum Therapeutics, Inc. Class A Common Stock has 38.39M shares outstanding. The count is up 36.54% from a year earlier.
Does CTNM pay a dividend?
No. Contineum Therapeutics, Inc. Class A Common Stock does not pay a dividend.
How much debt does CTNM have?
Contineum Therapeutics, Inc. Class A Common Stock has $0 of total debt and $75.20M of cash and equivalents, a net cash position of $75.20M.
CTNM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors